Introducing Webinar+, a chance to interact with the webinar speaker following the presentation. A live Q&A and discussion will immediately follow the presentation.
The last decade has seen significantly improved survival outcomes in patients with various cancers. Various childhood cancers, hematological cancers and testicular cancers have shown very good long-term survival after diagnosis and appropriate treatment of their malignancies. Cancer itself (e.g. testicular cancers) or various modalities of treatment including chemotherapy and radiation can affect gonadal function and fertility. Both primary and secondary hypogonadism can occur as a complication of cancer or its oncological treatment. Surgery or radiation to testes and gonadotoxic systemic chemotherapy results in primary hypogonadism; whilst surgery and or radiation involving pituitary and hypothalamic area can cause secondary hypogonadism. Development of type 2 diabetes mellitus, obesity and various lifestyle factors can contribute to secondary hypogonadism in cancer survivors. As the number of cancer survivors is on rise, it is important to develop appropriate awareness and education about these disorders among endocrinology practitioners to improve outcomes in terms of quality of life and fertility outcomes for these patients. In this presentation we aim to discuss various causes of gonadal dysfunction, diagnostic evaluation, and long-term management options for the cancer survivor men.
Physicians-in-Practice, Fellows, Residents, Nurse/Nurse Practitioner, Physician Assistant, Allied Health Professional
With completion of this webinar a learner should be able to:
1. Identify signs and symptoms of gonadal dysfunction among cancer survivor men.
2. Request for appropriate investigations.
3. Initiate hormone replacement therapy and lifestyle measures as appropriate.
4. Initiate appropriate treatment and referrals in relation to fertility related issues.
The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Endocrine Society has achieved Accreditation with Commendation.
AMA PRA Category 1 Credit
The Endocrine Society designates each activity in this course for a maximum of 1.00
AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.
Please note that while other accrediting bodies accept AMA PRA Category 1
credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.
Maintenance of Certification (MOC)
Successful completion of each CME activity in this course, which includes participation in the evaluation component, enables the participant to earn up to 1.00 points in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
For questions about content or obtaining CME credit, please contact the Endocrine Society at info@endocrine.org
FACULTY AND DISCLOSURES
Shaishav S. Dhage, MD ,DNB, MRCP, MRCP
Consultant Endocrinologist
Christie Hospital, Manchester, UK
Moderator:
Marcelo Correia, MD, MSc, PhD
STATEMENT OF INDEPENDENCE
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s peer reviewers.
DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.
The Endocrine Society staff involved in the development of this CME activity reported no relevant financial relationships.
The Endocrine Society staff have reviewed all disclosures and resolved or managed all relevant identified conflicts of interest, as applicable.